Safety and Efficacy Study of KP-1461 to Treat ART-Experienced HIV+ Patients
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to investigate the safety and efficacy of KP-1461 given
every 12 hours for 124 days to HIV+ patients who have failed multiple antiretroviral
regimens.